Telix Pharmaceuticals Limited Overview
Pro stress-test →Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. In February 2026, Telix reported full-year 2025 sales of US$803.79 million alongside a small net loss of US$7.13 million, with 2026 revenue guidance of US$950 million to US$970 million. The company is scaling its commercial footprint while expanding its radiopharmaceutical pipeline beyond prostate imaging into oncology therapeutics.
Strategic Profile
Pro stress-test →Telix is coupling higher revenue ambitions and capital-raising flexibility with efforts to broaden its oncology imaging portfolio into glioma, including use alongside its TLX101-Tx therapy program. The 2026 revenue guidance embeds a full year of contribution from the lower margin RLS network, while still leaning on Illuccix and Gozellix to carry the topline. However, the company faces near-term regulatory headwinds including SEC scrutiny and recent FDA rejections for pipeline candidates.
Competitive Landscape
Pro stress-test →To own Telix, you need to believe it can turn a growing radiopharmaceutical imaging franchise into a broader oncology platform while managing heavy reinvestment and regulatory complexity. Telix competes in the specialized radiopharmaceutical space with established diagnostic imaging revenue but faces competitive pressure in PSMA imaging. The company's differentiation lies in its vertically integrated manufacturing (RLS acquisition) and dual theranostic platform approach.
Industry Context
Telix Pharmaceuticals Limited operates in Biopharmaceutical - Radiopharmaceuticals / Oncology.
Key facts
Founded: 2015 · Headquarters: Melbourne, Australia · Revenue: $803.8M USD (2025) · Market cap: $3.31B AUD